Fig. 2

Galantamine-treatment inhibits leukocyte trafficking to inflammatory sites in FMF-KI mice. A, B Total number of cells in peritoneal washes (A) and total splenocyte counts (B) from galantamine- and PBS-treated FMF-KI mice at the end of 4–8 weeks of treatment (data presented as mean ± SEM; *P < 0.5 by Mann–Whitney U test). C Example flow cytometric analysis of splenic and peritoneal cells from galantamine- and PBS-treated FMF-KI mice after 4–8 weeks of treatment. Total splenocytes were analyzed for relative frequencies of CD11b⁺. The percentage of CD11b⁺ cells from the spleens of galantamine- and PBS-treated FMF-KI mice (n = 5 in each group) is shown next to the flowcytometry panels. D Total number of cells in a subcutaneous dorsal air pouch from galantamine- and PBS-treated FMF-KI mice after 6 days of treatment (data presented as mean ± SEM; *P < 0.05 by Mann–Whitney U test; WT is included for comparison only)